Immunotherapy has transformed the treatment landscape for advanced melanoma, but many patients either fail to respond or relapse after an initial benefit. A new study from H. Lee Moffitt Cancer Center, published in the Journal for ImmunoTherapy of Cancer, identifies a promising strategy to address this challenge: a three-drug immune checkpoint blockade that includes a target not yet part of standard clinical regimens, TIM-3.
Breaking through checkpoint resistance
Checkpoint inhibitors work by releasing the molecular “brakes” that cancers exploit to evade immune attack. Antibodies against programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) were the first to show survival benefits, and the addition of lymphocyte activation gene 3 (LAG-3) more recently strengthened responses in some patients. Still, resistance remains common, with no effective second-line therapies for those whose tumors progress.
Moffitt researchers, led by melanoma program director Keiran Smalley, PhD, focused on the role of T-cell immunoglobulin and mucin-domain containing protein 3 (TIM-3). This receptor marks terminally exhausted T cells incapable of mounting a strong antitumor response. “By blocking TIM-3 in addition to PD-1 and LAG-3, we saw a more powerful and targeted immune response, even in difficult-to-treat tumors,” Smalley said in the center’s announcement.
Preclinical evidence of tumor regression
The team tested multiple drug combinations in three well-established mouse melanoma models, including two resistant to current checkpoint therapies. While standard doublets delayed tumor growth, they failed to achieve durable responses. By contrast, the triplet targeting PD-1, LAG-3, and TIM-3 not only slowed progression but also drove complete tumor regressions in some animals.
Mechanistic studies revealed that the triple blockade reduced numbers of exhausted CD8+ T cells and regulatory T cells, while expanding populations of progenitor-like T cells with the capacity to sustain long-term immunity. Importantly, the triplet also increased tumor-specific T-cell infiltration, signaling a reinvigoration of antitumor immunity at both the tumor site and in draining lymph nodes.
To extend the findings beyond mouse models, the investigators analyzed single-cell RNA sequencing data from human melanoma samples. They found that TIM-3 expression was enriched in tumors from patients who had not responded to immunotherapy, and strongly correlated with PD-1 expression on CD8+ T cells. This pattern provides a biological rationale for co-targeting TIM-3 alongside other checkpoints in resistant disease.
Safety profile supports clinical translation
A key concern with triplet checkpoint blockade is toxicity. Immune-related adverse events often increase when additional pathways are inhibited. In this study, however, neither the PD-1/LAG-3/CTLA-4 nor the PD-1/LAG-3/TIM-3 triplet produced evidence of added toxicity in mice. Body weights remained stable, and histological analyses showed no abnormal immune infiltration in vital organs.
These preclinical findings echo early clinical data from other triplet regimens, such as the RELATIVITY-048 trial of PD-1, LAG-3, and CTLA-4 inhibitors, which also demonstrated tolerability.
Next steps toward the clinic
While the results are limited to preclinical models, they suggest that TIM-3–directed therapies could be valuable additions to the melanoma immunotherapy arsenal. With multiple anti–TIM-3 antibodies already in early-phase clinical development for various cancers, the groundwork for translation is in place.
“Our findings offer a new approach to treating melanoma in patients who currently have few options,” Smalley said. “We’re excited about the potential to bring this strategy to clinical trials and ultimately to patients.”
If confirmed in humans, the PD-1/LAG-3/TIM-3 triplet could represent the first rationally designed second-line immunotherapy for advanced melanoma—addressing a pressing need for patients who fail existing checkpoint combinations.
